These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Adjuvant chemotherapy for advanced endometrial cancer. Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785 [TBL] [Abstract][Full Text] [Related]
5. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574 [TBL] [Abstract][Full Text] [Related]
6. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis. Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895 [TBL] [Abstract][Full Text] [Related]
7. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma. Colomba E; Alexandre J; Le Teuff G; Genestie C; Coupez D; Coquard IR; Brachet PE; de Percin S; Sajous C; Fabbro M; Delanoy N; Joly F; Frenel JS; Pautier P; Leary A Gynecol Oncol; 2023 Feb; 169():78-84. PubMed ID: 36521352 [TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. Eskander RN; Sill MW; Beffa L; Moore RG; Hope JM; Musa FB; Mannel R; Shahin MS; Cantuaria GH; Girda E; Mathews C; Kavecansky J; Leath CA; Gien LT; Hinchcliff EM; Lele SB; Landrum LM; Backes F; O'Cearbhaill RE; Al Baghdadi T; Hill EK; Thaker PH; John VS; Welch S; Fader AN; Powell MA; Aghajanian C N Engl J Med; 2023 Jun; 388(23):2159-2170. PubMed ID: 36972022 [TBL] [Abstract][Full Text] [Related]
10. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187 [TBL] [Abstract][Full Text] [Related]
11. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. Westin SN; Moore K; Chon HS; Lee JY; Thomes Pepin J; Sundborg M; Shai A; de la Garza J; Nishio S; Gold MA; Wang K; McIntyre K; Tillmanns TD; Blank SV; Liu JH; McCollum M; Contreras Mejia F; Nishikawa T; Pennington K; Novak Z; De Melo AC; Sehouli J; Klasa-Mazurkiewicz D; Papadimitriou C; Gil-Martin M; Brasiuniene B; Donnelly C; Del Rosario PM; Liu X; Van Nieuwenhuysen E; J Clin Oncol; 2024 Jan; 42(3):283-299. PubMed ID: 37864337 [TBL] [Abstract][Full Text] [Related]
12. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. Pignata S; Califano D; Lorusso D; Arenare L; Bartoletti M; De Giorgi U; Andreetta C; Pisano C; Scambia G; Lombardi D; Farolfi A; Cinieri S; Passarelli A; Salutari V; De Angelis C; Mignogna C; Priolo D; Capoluongo ED; Tamberi S; Scaglione GL; Arcangeli V; De Cecio R; Scognamiglio G; Greco F; Spina A; Turinetto M; Russo D; Carbone V; Casartelli C; Schettino C; Perrone F Ann Oncol; 2024 Jul; 35(7):667-676. PubMed ID: 38704093 [TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites? Maiorano MFP; Messina C; Maiello E; Cormio G; Maiorano BA BJOG; 2024 Jul; 131(8):1157-1159. PubMed ID: 38164107 [TBL] [Abstract][Full Text] [Related]
15. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis. Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091 [TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
19. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192 [TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]